key: cord-1052634-7qb726dh authors: Gruell, H.; Vanshylla, K.; Tober-Lau, P.; Hillus, D.; Schommers, P.; Lehmann, C.; Kurth, F.; Sander, L. E.; Klein, F. title: mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant date: 2021-12-14 journal: nan DOI: 10.1101/2021.12.14.21267769 sha: ab5b14a450d883e92eff61fa5d8346ed7723bee8 doc_id: 1052634 cord_uid: 7qb726dh The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections in various countries. This new variant of concern carries an unusually high number of mutations in key epitopes of neutralizing antibodies on the spike glycoprotein, suggesting potential immune evasion. Here we assessed serum neutralizing capacity in longitudinal cohorts of vaccinated and convalescent individuals, as well as monoclonal antibody activity against Omicron using pseudovirus neutralization assays. We report a near-complete lack of neutralizing activity against Omicron in polyclonal sera after two doses of the BNT162b2 vaccine, in convalescent individuals, as well as resistance to different monoclonal antibodies in clinical use. However, mRNA booster immunizations in vaccinated and convalescent individuals resulted in a significant increase of serum neutralizing activity against Omicron. Our study demonstrates that booster immunizations will be critical to substantially improve the humoral immune response against the Omicron variant. Most approved COVID-19 vaccines are based on transient expression of the viral spike (S) glycoprotein (Wu01 strain) to induce SARS-CoV-2-directed immunity. 1 Mutations in antibody epitopes on the spike protein can result in increased viral resistance to neutralizing antibodies and have been associated with reduced vaccine effectiveness. 2 Moreover, they are able to strongly impair activity of monoclonal antibodies used for treatment and prevention of COVID- 19. 3 Shortly after its identification in the Gauteng province in South Africa, the Omicron variant (BA.1 sublineage of B.1.1.529) of SARS-CoV-2 was designated as a "variant of concern" (VoC) by the World Health Organization. Genomic surveillance and surrogate parameters (e.g., S gene target failure in diagnostic PCR) document a sharp rise in Omicron infections across the globe. 4 Moreover, the observation of increasing incidences in populations with high prevalence of SARS-CoV-2 immunity as well as reports of re-infections suggest potent immune evasion properties of the Omicron variant. 5 In comparison to previously described VoCs, the Omicron variant is notable for its high number of non-synonymous mutations relative to the ancestral Wu01 strain of SARS-CoV-2. The majority of these mutations are located in the viral spike glycoprotein and include critical epitopes for SARS-CoV-2-neutralizing antibodies in the Nterminal domain and the receptor-binding domain. Several of these mutations have already been associated with resistance to SARS-CoV-2-or vaccine-induced neutralizing antibodies. 3, 6, 7 Therefore, the spread of the Omicron variant can have important implications on current strategies to prevent and treat COVID-19, and may require urgent public health interventions to limit transmission and morbidity. To determine the susceptibility of the Omicron variant to vaccine-induced serum activity, we analyzed samples obtained from 30 individuals with no evidence of prior infection. 8 Samples were collected one month (median 3.9 weeks; range 2.9-6.0 weeks) after completion of a twodose course of the BNT162b2 vaccine (Fig. 1a) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint samples showed high levels of neutralizing activity against the Wu01 strain with a geometric mean 50% inhibitory serum dilution (GeoMean ID50) of 546 (Fig. 1a) . Serum neutralizing activity against the Alpha, Delta, and Beta variant was decreased to GeoMean ID50s of 331, 172, and 40, respectively (samples that did not achieve 50% inhibition at the lowest tested dilution of 10 were imputed to an ID50 of 5). Notably, only eight out of the 30 vaccinated individuals (27%) displayed detectable serum neutralizing activity against Omicron, resulting in a GeoMean ID50 of 8 (Fig. 1a) , which was significantly lower than against the Beta variant (P<0.0001), one of the most immune evasive variants previously described. (Fig. 1c) . In addition, serum was obtained one month after administration of a single dose BNT162b2 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint resulting in a "hybrid immunity" acquired by a combination of infection and vaccination (Hybrid time point; Fig. 1c ). Early after infection, neutralizing activity against Wu01 was relatively variable, ranging in ID50s from 37 to 11,008, with a GeoMean ID50 of 494 that decreased to 93 after 12 months (Late). Following a single BNT162b2 dose, all convalescent individuals had a strong increase in neutralizing serum activity resulting in a GeoMean ID50 of (imdevimab), and S309 (sotrovimab)) ( Table 1 ). All antibodies were tested in parallel against the Wu01 strain as well as the Alpha, Beta, Delta, and Omicron variants. While all antibodies showed neutralizing activity against Wu01 and Alpha, only 7/9 and 5/9 showed neutralizing activity against the Delta and Beta variants, respectively ( Table 1) . Notably, neutralizing activity against the Omicron variant was abolished in seven out of nine antibodies ( Table 1) . We conclude that the neutralizing activity of several monoclonal antibodies is strongly affected against the Omicron variant and will limit treatment options for Omicron-induced COVID-19. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint The rapid surge in Omicron variant infections poses a significant challenge to public health. 4 Our study demonstrates marked resistance of the Omicron variant to serum neutralizing activity induced by two doses of the BNT162b2 vaccine or SARS-CoV-2 infection. Lower neutralizing titers have been associated with an increased risk of symptomatic COVID-19, suggesting that limited neutralizing activity against Omicron may result in increased risk of infection and higher burden of disease. 13 Whether cellular immunity will be effective in preventing severe disease after Omicron infection in the absence of a potent neutralizing antibody response remains to be determined. 14,15 Importantly, a single BNT162b2 booster immunization effectively induced a substantial increase in serum neutralization against the Omicron variant and resulted in neutralizing titers similar to those observed against Wu01 after two doses of BNT162b2. It can be speculated that the extent of the potent neutralizing response against the Omicron variant following booster vaccination may be a consequence of ongoing affinity maturation following initial vaccination or SARS-CoV-2 infection with the ancestral spike protein. [16] [17] [18] While variant-specific vaccines and novel monoclonal antibodies may be required for optimal activity, our data provide clear evidence that booster immunization with an available vaccine induces robust neutralization against the immune evasive Omicron variant. In addition to the critical need for rapidly making vaccines globally available and accessible to counter the emergence of novel variants, booster campaigns may provide an immediate and effective intervention against Omicron. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Pseudovirus neutralization assays were performed as previously described using a single-round infection lentivirus-based system 9, 19 . Pseudovirus particles were generated in HEK293T cells by co-transfection of plasmids encoding for the SARS-CoV-2 spike protein, HIV-1 Tat, HIV-1 Gag/Pol, HIV-1 Rev, and luciferase followed by an IRES and ZsGreen using FuGENE 6 Transfection Reagent (Promega). Culture supernatants were changed to fresh medium 24 hours . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint after transfection, and pseudovirus-containing supernatants were harvested at 48 h to 72 h post transfection. Following centrifugation and filtration (0.45 µm), pseudoviruses were stored at -80°C until use. Pseudoviruses were titrated by infecting 293T-ACE2 cells and luciferase activity was determined following a 48-hour incubation period at 37°C and 5% CO2 by addition of luciferin/lysis buffer (10 mM MgCl2, 0.3 mM ATP, 0.5 mM Coenzyme A, 17 mM IGEPAL (all Sigma-Aldrich), and 1 mM D-Luciferin (GoldBio) in Tris-HCL) using a microplate reader (Berthold). Pseudovirus dilutions resulting in an at least 1000-fold difference in relative light units (RLUs) between infected and non-infected 293T-ACE2 cells were used for neutralization assays. Serum samples were heat-inactivated at 56°C for 45 min prior to use. Serial dilutions of serum (1:3 dilution series with a starting dilution of 1:10) and monoclonal antibodies (1:5 dilution series with a starting concentration of 10 µg/ml) were co-incubated with pseudovirus supernatants for one hour at 37°C prior to addition of 293T-ACE2 cells. Following a 48-hour incubation at 37°C and 5% CO2, luciferase activity was determined as described above. Serum samples were tested in single dilution series and monoclonal antibodies were tested in duplicates. Background RLUs of non-infected cells were subtracted, and the serum ID50s and antibody IC50s were determined as the serum dilution and antibody concentration resulting in a 50% RLU reduction compared to virus-infected untreated controls cells using a non-linear fit model to plot an agonist vs. normalized dose response curve with variable slope using the least squares fitting method in GraphPad Prism 7.0 (GraphPad). Wilcoxon matched-pairs signed rank test. Serum samples that did not achieve 50% inhibition at the lowest tested dilution of 10 (lower limit of quantification, LLOQ) were imputed to ½ of the LLOQ (ID50=5) for graphical representation and statistical evaluation. All data are included in the figure, table, and supplement of this manuscript. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint Not applicable. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.14.21267769 doi: medRxiv preprint This work was supported by grants from COVIM ), by the German Center for Infection Research (DZIF) (to F.Kl.), and the DFG CRC1279 and CRC1310 Writing -Review & Editing, all authors; Visualization SARS-CoV-2 vaccines in development Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization SARS-CoV-2 variants of concern and variants under investigation in England Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Adaptive immunity to SARS-CoV-2 and COVID-19 mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations Evolution of antibody immunity to SARS-CoV-2 Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays We are grateful to all study subjects for their participation in our studies. We thank M. Augustin, H.G., K.V., and F.Kl. are listed as inventors on pending patent application(s) on SARS-CoV-2-neutralizing antibodies filed by the University of Cologne.